Glial fibrillary acidic protein in Guillain-Barré syndrome: Methodological issues
✍ Scribed by A. Petzold; L. Rosengren; M.M. Verbeek; Francesca Notturno; Christina M. Caporale; Angelo DeLauretis; Antonino Uncini
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 51 KB
- Volume
- 39
- Category
- Article
- ISSN
- 0148-639X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
An earlier investigation from our laboratory (Ilyas AA, Willison HJ, Quarles RH, et al. Serum antibodies to gangliosides in Guillain-Barre syndrome. Ann Neurol 1988;23:440-447) demonstrating the presence of high levels of antiganglioside antibodies in the sera of 5 of 26 patients with Guillain-Barre
## Abstract Early predictors of prognosis in Guillain‐Barré syndrome (GBS) are needed to identify patients who are likely to make a poor recovery and to guide therapeutic decision‐making in the acute phase. Here we investigate whether axonal protein biomarkers released into the cerebrospinal fluid
We measured the autoantibodies to GM1, central myelin proteins, and cardiolipin in 30 GBS patients using sensitive ELISA and Western blot techniques. The sequential modifications of titers during plasma-exchange (PE) and at follow-up were investigated in 15 patients. In pretreatment sera, we found s
## Abstract The molecular characteristics of hepatitis A virus (HAV) have been studied widely though there is a paucity of data on the correlation with virological and serological findings. In the present study, the whole genome of an Indian HAV strain associated with Guillain–Barré syndrome (GBS)